Menu
Back to Journals » Clinical Interventions in Aging » Volume 4
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Authors Sethi R, Sanfilippo N
Published 5 June 2009 Volume 2009:4 Pages 259—267
DOI https://doi.org/10.2147/CIA.S4885
Review by Single anonymous peer review
Peer reviewer comments 3
Rajni Sethi, Nicholas Sanfilippo
Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, USA
Abstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.
Keywords: prostate cancer, leuprorelin, hormonal deprivation therapy
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.